報價延遲最少15分鐘:2026/04/21 23:58 EDT
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
2.17 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-2.52/-1.35
|
|
企業價值
8.35M
|
| 資產負債 |
|
每股賬面淨值
2.03
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
88.60K
|
|
每股收益
0.02
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| Creative Medical Technology Holdings Inc is a commercial-stage biotechnology company focused on the advancement of regenerative therapies in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics. Its pipeline consists of AlloStem (CELZ-201-DDT); ImmCelz (CELZ-100), a personalized supercharged immune therapy platform; CELZ-201 CREATE-1, an intervention for the treatment of recent onset Type 1 Diabetes; AlloStemSpine for treatment of lower back pain; the Alova program to treat infertility as a result of premature ovarian failure; and other regenerative treatment programs and technologies like OvaStem, CaverStem, FemCelz, StemSpine, and others for the treatment of various indications related to sexual health, spine disc disease, kidney failure, liver failure, etc. |
